Crescendo Biologics Appoints Chair

Crescendo Biologics Ltd. has appointed Kevin Johnson non-executive chair of the board of directors – effective immediately. Johnson has 27 years' experience in antibody development and previously was CEO of Netherlands-based PanGenetics, an antibody development company. He also held various roles at Cambridge Antibody Technology, which eventually led to his appointment as research director and chief technology officer. Since 2003 he has been working in the life science team at Index Ventures.

Crescendo Biologics Ltd. has appointed Kevin Johnson non-executive chair of the board of directors – effective immediately. Johnson has 27 years' experience in antibody development and previously was CEO of Netherlands-based PanGenetics, an antibody development company. He also held various roles at Cambridge Antibody Technology, which eventually led to his appointment as research director and chief technology officer. Since 2003 he has been working in the life science team at Index Ventures.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

BREAKING NEWS: Merck & Co. Leaps Into COPD Space With $10bn Verona Buy

 
• By 

The UK firm's chronic obstructive pulmonary drug Ohtuvayre has been enjoying a stellar launch.

Wave of Biopharma Licensing Deals in India: ‘The Model Is Working’

 

From vonoprazan and inclisiran to nirsevimab, big pharma has licensed several products to Indian firms as have other biopharma players. Experts discuss the intricacies of such licensing deals amid signs of more action in store and whether geopolitics could dull partnering with Chinese firms.

Actithera Raises $75m To Enter Competitive FAP-Targeting Radioligand Field

 

While companies such as Eli Lilly and Roche have faced setbacks to their fibroblast activation protein-targeting oncology therapies, Actithera believes its radiopharmaceuticals platform will prove more successful.

Concentra Picks Up Cargo In Latest Troubled Biotech Buyout

 

The Kevin Tang-led firm will pay $4.38 per share for Cargo, which laid off most of its workforce following the failure of a Phase II CAR-T trial.

More from Scrip

Actithera Raises $75m To Enter Competitive FAP-Targeting Radioligand Field

 

While companies such as Eli Lilly and Roche have faced setbacks to their fibroblast activation protein-targeting oncology therapies, Actithera believes its radiopharmaceuticals platform will prove more successful.

J&J Seeks Schizophrenia Relapse Indication For Caplyta

 

The company is expecting US FDA approval of the drug in a bigger indication, major depressive disorder, later this year.

Concentra Picks Up Cargo In Latest Troubled Biotech Buyout

 

The Kevin Tang-led firm will pay $4.38 per share for Cargo, which laid off most of its workforce following the failure of a Phase II CAR-T trial.